Compare Monolithic Power Systems Inc (MPWR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Pfizer Inc — how do they compare? Monolithic Power Systems Inc trades at $1,391.28 (market cap $67.32B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2.4× Monolithic Power Systems Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Pfizer Inc for 158 Days on average.
| MPWR | PFE | |
|---|---|---|
Market Cap | $67.32B | $159.59B |
Volume | 826,960 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $1.69K | $29.02 |
52-Week Low | $856.96 | $23.67 |
Typical Hold Time | 25 Days | 158 Days |
Enterprise Value | $65.92B | $211.09B |
Dividend Yield | 0.58% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,425.98, down 3.24% on the day, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 24.5% net income margin and 21.98% ROE, though valuation metrics remain elevated at 87 P/E. Recent earnings beats and a manufacturing partnership with GlobalFoundries signal continued growth potential in AI and data center markets.
MPWR presents a compelling growth story driven by AI infrastructure demand, but faces valuation concerns and insider selling pressure. The stock's 88% buy rating consensus and $1,830 price target suggest 28% upside potential, though investors should weigh premium valuation against strong execution and market positioning.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
